POH1 activators are specialized chemicals designed to modulate the activity of the POH1 protein, also known as the proteasome deubiquitinating enzyme Rpn11. POH1 is a critical component of the 19S regulatory particle of the 26S proteasome, an enzymatic complex responsible for the targeted degradation of ubiquitinated proteins in eukaryotic cells. By cleaving ubiquitin moieties from proteins destined for degradation, POH1 ensures the recycling of ubiquitin and regulates the protein turnover essential for various cellular processes.
The activation of POH1 through chemical means can be achieved either directly or indirectly. Direct activators might interact with the POH1 enzyme at its active site or at allosteric sites, influencing its deubiquitinating activity. Such interaction could result in a conformational change that enhances the enzyme's catalytic efficiency, leading to an increased rate of ubiquitin cleavage from substrates. This would effectively streamline the proteasomal degradation pathway and could influence the fate of proteins that are regulated by ubiquitination. Indirect activators of POH1 may work by influencing the cellular pathways that regulate the proteasome function. These could include signaling molecules that modulate the expression levels of POH1, the assembly of the 19S regulatory particle, or the overall structure and function of the 26S proteasome. Additionally, post-translational modifications of POH1 or associated regulatory subunits, which may be affected by indirect activators, can play a role in modulating the activity and specificity of the proteasome.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
A proteasome inhibitor that prevents protein degradation. By inhibiting the proteasome, MG-132 can indirectly enhance the necessity for deubiquitinating enzymes like POH1. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Another proteasome inhibitor that can potentially increase the demand for deubiquitinating activity of POH1. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $41.00 | ||
An inhibitor of the 20S proteasome, influencing protein degradation processes and possibly implicating POH1 indirectly. | ||||||
Ixazomib | 1072833-77-2 | sc-489103 sc-489103A | 10 mg 50 mg | $311.00 $719.00 | ||
Proteasome inhibitor that can influence the proteasomal degradation pathway, potentially affecting POH1 activity indirectly. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Known to inhibit the proteasome and could indirectly increase the demand for POH1's deubiquitinating function. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
A selective proteasome inhibitor that can influence the degradation pathway, potentially implicating POH1. | ||||||
ONX 0914 | 960374-59-8 | sc-477437 | 5 mg | $245.00 | ||
Inhibits the immunoproteasome subunit LMP7 and can modulate proteasome activity, potentially influencing POH1. | ||||||
Delanzomib, free base | 847499-27-8 | sc-396774 sc-396774A | 5 mg 10 mg | $160.00 $300.00 | ||
An inhibitor of the proteasome, influencing the degradation pathway and possibly affecting POH1 indirectly. | ||||||
Oprozomib | 935888-69-0 | sc-477447 | 2.5 mg | $280.00 | ||
A proteasome inhibitor that can modulate the degradation pathway, potentially implicating POH1. | ||||||